GLP-1 Price Guide Compare prices
About this publication

About GLP-1 Price Guide

An independent editorial resource for understanding the real cost of online compounded GLP-1 treatment.

Updated June 1, 2026Independent editorialEmail: glponepriceguide@gmail.com
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

About GLP-1 Price Guide

GLP-1 Price Guide is an independent editorial resource built to help patients understand the real cost of online weight-loss treatment with compounded GLP-1 medications. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment.

Our Editorial Mission

"Compare the real GLP-1 cost — not just the advertised starter price."

The compounded GLP-1 market grew rapidly in 2024-2025 during the FDA semaglutide and tirzepatide shortages. Many telehealth providers advertise low "starting at" prices that don't reflect true monthly cost after dose escalation, refills, and membership fees. We exist to make the real cost visible.

What We Cover

Editorial Independence

GLP-1 Price Guide is an editorial publication. We do not accept paid placements that influence our pricing analysis or transparency assessments. If we maintain an affiliate, sponsorship, or material relationship with any provider mentioned, that relationship is disclosed on the relevant page.

Pricing Verification

Pricing is re-verified the 1st of each month from publicly available provider pages and third-party references. We do not invent pricing numbers; every figure cited is sourced. Where a provider has not disclosed pricing publicly, we mark it "verify" rather than guess.

Medical & Regulatory Position

Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. We avoid equivalence claims and avoid recommending unlicensed "research peptide" vendors. We support patient-physician decision-making, not direct-to-consumer prescribing.

Contact

Editorial inquiries, corrections, and pricing updates: glponepriceguide@gmail.com

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.